Invention Grant
- Patent Title: 2,6,7,8 substituted purines as HDM2 inhibitors
- Patent Title (中): 2,6,7,8取代嘌呤作为HDM2抑制剂
-
Application No.: US14762827Application Date: 2014-01-29
-
Publication No.: US09540377B2Publication Date: 2017-01-10
- Inventor: Carolyn Michele Cammarano , Matthew P. Christopher , Christopher Dinsmore , Ronald J. Doll , Francesc Xavier Fradera Llinas , Chaomin Li , Michelle Machacek , Michelle Martinez , Latha G. Nair , Weidong Pan , Michael Hale Reutershan , Manami Shizuka , Dietrich P. Steinhuebel , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Yaolin Wang , Liping Yang , Stephane L. Bogen , Matthew E. Voss , Jagannath Panda , Anthappan Tony Kurissery
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Yong Zhao; John C. Todaro
- International Application: PCT/US2014/013566 WO 20140129
- International Announcement: WO2014/120748 WO 20140807
- Main IPC: A61K31/52
- IPC: A61K31/52 ; C07D473/16 ; C07D473/00 ; C07D473/34 ; C07D473/30
Abstract:
The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Public/Granted literature
- US20150353553A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS Public/Granted day:2015-12-10
Information query
IPC分类:
